Recently, advances in wearable technologies, data science and machine learning have
begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of …

Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …

Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

Living guidelines are routinely updated guidelines that are developed for selected topic
areas with rapidly evolving evidence that drives frequent change in clinical practice. These …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Contemporary anticancer drugs have significantly improved cancer survival at the expense
of cardiovascular toxicities, including heart disease, thromboembolic disease, and …

Rearranged during transfection (RET) is involved in the physiological development of some
organ systems. Activating RET alterations via either gene fusions or point mutations are …